Hyperhomocysteinemia is ariskfactor forvenous thrombosis, but the underlying mechanismi su nclear.Ift he thiol-group of homocysteine interferes with components of the clotting system,we expect thathigh cysteinewill be alsoariskfactor forvenous thrombosis.I fh igh homocysteine reflects ad isturbed methyl-group donation by S-adenosylmethionine, we expect thatl ow methionine will be ar iskf actor fort hrombosis.We performedacase-controlstudy in 185patientswith recurrent venous thrombosis and in 500 control subjects. We determinedm ethionine,h omocysteine, cysteine and assessedt he associated thrombotic risk. Lowf astingm ethionine wasa ssociated with an increasedr isko nr ecurrent venous Keywords Methionine,homocysteine, cysteine,venous thrombosis thrombosis [OR bottomv s. top quartile =3 .3 (95%CI 1.9-5.7)]. Low methionine remainedar iskf actor [OR bottomv s. top quartile =3 .5 (95%CI 2.0-6.0)] after adjusting forhomocysteineand cysteine, whereas thethrombotic risk forhomocysteinewas lost [OR= 1.0 (95%CI 0.6-1.9)] after adjustment.Cysteine yielded ah ighest odds ratio of 2.1 top vs.bottom quartile (95%CI 1.0-4.0) after adjustment.Inconclusion, we found thatlow fasting methionine is ariskfactor forr ecurrent venous thrombosis.This risk association was strongerf or methioninet han forh omocysteineo r cysteine.This supports the hypothesisthat impairedmethylation maybeinvolved in the pathogenesisofvenous thrombosis.
Introduction
Hyperhomocysteinemia is associatedwith the occurrence of arterial vasculard iseasea nd venous thrombosis (1) (2) .S everal mechanisms have beensuggestedtoexplain the relationshipbetween homocysteine and thrombotic disease. Onehypothesis is that the thiol-group of homocysteine interferes with components of the clotting system (3) (4) (5) (6) .Ifthis is true, it could be expected that other thiol-containing compounds, likecysteine, whichhas aclose structural similarity to homocysteine,also have thrombogenic properties. Cysteine could therefore alsobearisk factor forthrombosis, whereas methionine,which does not have athiolgroup, would not be expected to be associated with an increased risk of thrombosis.
Another hypothesis focuses on amainpurpose of the homocysteine metabolism, namelythe donation of amethylgroupby S-adenosylmethionine (AdoMet) (Fig. 1) , whichisusedinmany cellularm ethyltransferasep rocesses,i ncluding methylation of DNA, RNA, lipids and proteins. Ashortage of methionine leading to lowAdoMet levels could influences everal of the mentionedmethylation processes, forinstanceDNA methylation (7) , whichinturncould contribute to the pathologicalcascade leading to venous thrombosis.Ifthis hypothesis is true, hyperhomocysteinemia is merelyam arker of an impaired metabolismo f methyl groups, and one could expectthat other metabolites that reflect this process, for instancelow methionine,could also be risk factorsf or thrombosis.H ypercysteinemia, on the other hand,does not reflect this process, so it would not be expected to be arisk factor forthrombosis.
In ordertodetermine whichofthe above hypothesesismore likely, we performed ac ase-controls tudy and investigated the risk of recurrent venous thrombosis for metabolites and vitamins of the homocysteine metabolism, i.e. methionine, homocysteine, cysteine,betaine, plasma folate and red blood cell folate. We also investigated whether risk associations were modifiedb yc ompounds of the homocysteine metabolism or by the factor V Leiden or prothrombin 20210G>Amutation.
Methods

Subjects
Forthe current study,weusedsamples of apreviouslypublished case-control study (8, 9) . In the Netherlands, virtuallya ll patients with ah istoryo fv enous thrombosis are registered at an anticoagulant clinic.W eapproached473 patients whohad had twoormore episodesofvenous thrombosis and invitedthem to takepartinthis study.Ofthose 473 patients, 185 patients (39%) agreed to participate.
Through ageneral practiceinThe Hague, 2,812 possible control subjects between20and 90 years of age were invitedbyletter to participate in as tudy on risk factorsf or cardiovasculard isease. Five hundredn inety-one (21%) responded positively and subsequentlyr eceiveda dditional information by mail, after which532 subjects agreed to participate. Of those 532 subjects, 10 as yetr efusedb ecauseo fp sychiatric problems (1), myocardial infarction (1),back pain(1) and undefined reasons (7) .Of the 521 subjectsleft,18did not showupfor blood sample collection, one subject refusedvenipunctureand for twosubjects venipuncturew as notp ossible. This left5 00 control subjects who participated in the study.The onlyexclusion criterion waspregnancy.
The study wasa pprovedb yt he ethics committee of the LeyenburgH ospital, and informed consent waso btained from all participants. 
Methods
Becauseamino acidlevelsare influenced by diet, blood samples of all 185 patients and 500 control subjects were collected after overnightfasting. Thesamples were obtainedfrom the antecubitalveinin4.5-ml EDTAvacuumglass tubes. They were used to determine the plasma concentrations of methionine,h omocysteine, cysteine,folate, vitamin B12, vitamin B6 and vitamin B2 (riboflavin) and for detecting the methylenetetrahydrofolatereductase (MTHFR)6 77C>T,f actor VL eiden (1691G>A) and prothrombin20210G>Apolymorphism.
The blood samples for plasma determinations were immediatelyplaced on iceand centrifugedat3,500 gfor 5min within twohours. The plasma wasseparated and storedat-20 ºC until analysis. Totalcysteine and total homocysteine concentrations in plasma were measured by an automated high-performance liquid chromatographym ethodw ith fluorescent detection,e ssentiallya ccording to the method by Fiskerstrand et al. ( 10) whichwas slightlymodified (11) .The inter-and intra-runcoefficient of variation waslessthan 6.5% for homocysteine concentrations (11) and less than 5% for cysteine levels (12) . Concentrations of methionine in plasma were determinedbyamodification of am ethodb ased on normal phasel iquid chromatography-tandemmassspectrometry (13) . Because methionine is oxidisedd uring storage,w ec alculated the totalm ethionine concentration as the sum of methionine and methionine sulfoxide.The inter-a nd intra-runc oefficient of variation for methionine levels wasabout 5%. Folate and vitamin B12 concentrations were measured in plasma samplesstored at -70ºCwith the Dualcount SPNB( solid phase no boil) Radioassay( DiagnosticP roduct Corporation,L os Angeles, CA, USA). Vitamin B6 (sumofp yridoxal 5'-phosphate and pyridoxal)and vitamin B2 were measured with liquid chromatography-tandem mass spectometry (14) . MTHFR6 77C>T,f actor VL eiden and prothrombin 20210G>A genotyping wasp erformed as previously described (9) .
Statisticalanalysis
Becausew eu sedd atao fap reviouslyp erformed case-control study we calculated the "smallest detectable relativerisk" (alpha 0.05 and power0.8), whichwas 1.67 foranodds ratio (OR) above 1. Group characteristics aregiven as medians and ranges.
To investigateapossible dose-response relationship, we used the following logistic regression models: First,au nivariate analysis wasc arried outf or each of the variablesm ethionine, homocysteine and cysteine.Second, each analysis wasrepeated with the additionalcovariablessex and age. Third, the variables methionine,h omocysteine, cysteine,a ge and sexw ere alli ncludedand evaluatedinone multivariate model. In an additional analysis, secondo rder termsw ere includedi nt he models to check for possible non-linearity and interactions (effect modification).Wecalculated 95%confidenceintervals (95%CI) for the OR.
Foreasyinterpretation of the results, the OR could be interpreted as the relative risk to develop recurrent venous thrombosis for quartiles of the continuous variables. We used either the top quartileorthe bottom quartileasareference group. Because we did ac ase-controls tudy in patients with recurrent venous thrombosis,the OR might be higher than expected for first-time venous thrombosis.
To evaluate apossible effect modification we calculated the relativerisks for combinations of quartiles. Forthe combination of methionine and homocysteine, we used subjects with low homocysteine and high methionine as areference group. Forthe combination of methionine with cysteine,weusedsubjects with lowcysteine and high methionine as areference group.
Furthermore,weinvestigated the joint effectsfor methionine in combination with the factor VL eiden,p rothrombin 20210G>A andM THFR 677C>T mutation. When the number of homozygote genotype variantswas too small, as in the caseof factor VLeiden,heterozygotes and homozygoteswere takentogether. We used subjects that had high methionine levels (top quartile)and wildtype factor VLeiden,prothrombin 20210G>A or wildtype MTHFR 677 C>T as areference group.
We also investigated the risk of recurrent venous thrombosis associated with methionine concentrations belowthe median for subgroups of the MTHFR 677C>T mutation. Subjects with a methionine concentration above the medianw ere the reference group.
Results
Baselinecharacteristics areshown in Figure 1 . There wasnosignificant correlation in control subjectsbetween methionine and homocysteine concentration (r= -0.02; p=0.72) and aweak correlation between methionine and cysteine concentration (r= -0.10; p=0.03). Homocysteine and cysteine levels were moderatelycorrelated (r=0.329; p<0.001).
Univariate analysis
We found methionine to be associatedwith agradual increased risk (P for trend=<0.001) of recurrent venous thrombosis with an age and sex-adjusted OR of 3.3 (95%CI 1.9-5.7) for am ethionine concentration below20.6 µM ( Table 1 ). The thrombotic risk associated with homocysteine wasalso dose-dependent(P for trend=0 .01), with ah ighest adjustedr isk of 1.4 (95%CI 0.8-2.4) for the top quartile(Table1). We also calculated the risk of recurrent venous thrombosis for subjects with ahomocysteine concentration above the 90 th percentile, whichy ieldeda na djusted (age and sex) OR of 1.7 (95%CI 1.1 to 2.8), whichisin line with previously published results ( 8, 9) . Forc ysteine the dose response relationshipwas attenuated(Pfor trend= 0.3) after adjusting for age and sexwith ahighest oddsratio of 1.9 (95%CI 1.0-3.4) for the top quartile.
Multivariate analysis
When the relativerisks associatedwith quartilesofmethionine, homocysteine and cysteine levels were notonlyadjusted for age and sexbut also for each other,low methionine remained associated with an increased risk of venous thrombosis [OR=3.5 (95%CI 2.0-6.0)] whereas the thrombotic risk associated with homocysteine levels waslost for everyofthe upper threequartiles[ OR=1.0 (95%CI 0.6-1.9)] ( Table 2) . Cysteine yielded a highest OR of 2.1 (95%CI 1.0-4.0) for the top quartile.
Effect modification
We calculated the OR for quartilesofmethionine levels in combination with quartiles of homocysteine (Table 3) or cysteine concentrations (datan ot shown).The risk on recurrent venous thrombosis remained high in the bottom quartileoffasting methionine concentrations independent of homocysteine (Table 3) or cysteine (datanot shown).
We repeated the analyses with adjustment for vitamin intake, smoking and blood levels of plasma folate, vitamin B12, vitamin B6 and vitamin B2. We found thatlow methionine is arisk factor for recurrent venous thrombosis independent of these variables(data not shown).
Next,weinvestigated apossibleinteraction between methionine andfactorVLeiden or prothrombin 20210G>A, i.e.well-established genetic riskf actors for venous thrombosis. Thes ame analysis wasperformedfor the MTHFR 677C>Tmutation. The combination of lowmethionine concentration (bottom quartile) and factorVLeiden yieldedanadjusted(ageand sex) OR of 15.9 (95%CI 5.5 to 45.9). In comparison, the OR for subjects with low methionine levels and no factorVLeiden was3.9 (95%CI 2.0 to 7.7) anditwas 9.9 (95%CI 3.1 to 32.0) for subjects with factorV Leiden and high methionine levels (topq uartile). However, because of the wide confidencei nterval no conclusive interpretations could be made aboutapossiblebiological interaction. No clear interaction wasfound between lowmethionine andthe prothrombin20210GA mutation or the MTHFR 677TTmutation.
Because the MTHFR 677TT genotype is amodest risk factor forvenous thrombosis and is associatedwith elevatedhomocysteine levels, we performed an analysis to investigatewhetherthe thromboticr isk associatedw ith methionine levels belowt he median differeda ccording to MTHFR genotype.M edian methionine levels were similarincontrol subjects with the MTHFR 677TT genotype [23.6 µM (range 13.6 to 58.4)] and the MTHFR 677CC genotype [24.0 µM (range 16.7 to 37.6)].The highest risk association for am ethionine concentration belowt he median wasfound in subjects with the MTHFR 677TT genotype,yielding an odds ratio of 3.0 (95%CI0 .7-12.6). Fort he MTHFR 677CC group we found an OR of 2.0( 95%CI 1.1-3.5) for the risk of recurrent venous thrombosis associated with methionine levels belowt he median. However, because of the wide confidenceintervals no conclusiveinterpretations canbedraw.
Discussion
The main finding in this study is that lowfasting methionine levels (< 20.6 µM)are associated with a3.3-fold (95%CI 1.9-5.7) increased risk of recurrent venous thrombosis.I na ll analyses, whether multivariate or univariate, adecreaseinmethionine levels wasassociatedwith an increased risk of venous thrombosis. Furthermore, we found thatm ethionine hasastrongerr isk association with recurrentv enous thrombosis thanhomocysteine or cysteine.The thromboticrisk associatedwith methionine le- vels belowthe median washighest in subjectswith the MTHFR 677TT genotype.The combination of lowmethionine and factor VL eiden yielded an OR of 15.9 (95%CI 5.5-45.9). However, confidenceintervals were too widetomakeconclusive interpretations about apossible biologicalinteraction from the latter observation. Cysteine yieldedahighest oddsratio of 2.1 (95%CI 1.0-4.0) for the top quartileafter adjustment. Them echanisms by whichh yperhomocysteinemia may causethrombotic disease arepoorlyunderstood. Homocysteine is asulfur-containing amino acid that canonlybeformed from methionine (Fig. 1) . Methionine is ap recursor of S-adenosylmethionine (AdoMet), whichservesasamethyl donor in transmethylation reactions. Demethylation of AdoMet results in the formation of S-adenosylhomocysteine (AdoHcy), whichi sh ydrolyzedt oh omocysteine and adenosine. Homocysteine is degraded viat he transsulfuration pathway or salvagedv ia remethylation to methionine (15) . Homocysteine can be remethylated by methionine synthase for which5-methyltetrahydrofolate is as ubstrate and vitamin B12 is ac ofactor.Ana lternativer emethylation pathway is catalyzed by betaine-homocysteine methyltransferase (BHMT),w hich uses betaine as am ethyldonor.
The first hypothesis we investigated involves an impaired methylation pathway resulting in areduced availability of methyl groups for methylation reactions,which mayhaveapossible role in the development of venous thrombosis (7) .I ft his is true, homocysteine is just amarker,and other metabolites that reflect this process, for instancelow methionine,could also be expected to confer an increased thromboticrisk. Thefindingthat lowmethionine is associatedwith athree-fold increased risk of recurrent venous thrombosis and that it is astronger risk factor than high homocysteine or high cysteine,isinline with this hypothesis.
The loss of thrombotic risk for homocysteine after adjustment for methionine and cysteine levels and the finding that methionine has as tronger risk association with recurrentv enous thrombosis is of interest and could suggest thatmethionine is a better markerfor risk assessment of recurrent venous thrombosis. Quéré et al. (16) also found lowmethionine to be stronger associatedwith venous thrombosis than hyperhomocysteinemia in TheM THFR 677C>T mutation also hasb een associated witha ni ncreased risk on venous thrombosis (2),w hich is thought to be due to elevation of homocysteine.W efound that the risk of recurrent venous thrombosis associated with am ethionine levelbelow the medianishighest in subjectswith the MTHFR 677TT genotype,which in theorycould also explain the association betweenMTHFR 677TT and venous thrombosis.
Becaused eterminants of methionine levels are poorly studied, it is difficulttoindicate causes underlying lowmethionine levels. It could be possible thatalowplasma methionine level is the result of alow intake of methionine. Another explanation could be impairedremethylation of homocysteine to methionine. In subjects with homocystinuria severe MTHFRd eficiencyi s oftenaccompaniedb ylow methionine levels (17) . However, in our studywedid not find significantly lowermethionine levels in subjectsw ith the MTHFR 677TT genotype,w hich causes a mildlyr educed enzyme activity and increased thermolability (18) .
Theotherh ypothesis tested in our study wasthe role of the thiol-group of homocysteine (3) (4) (5) (6) .Ifthe thiol-group of homocysteine is involved in thrombogenesis, it might be expected that cysteine,asulfhydryl amino acid whichisstructurally very similar to homocysteine,isalso associatedwith an increased risk of thrombosis. We found no dose-responser elationship between cysteine levels and the risk of venous thrombosis after adjustment for age and sex. However, high cysteine levels (top quartile) were associated with atwo-foldincreased thromboticrisk after adjusting for age and sex. With regard to this data we cannot draw solid conclusions whether cysteine is arisk factor forrecurrent venous thrombosis.W ef ound some other studies that investigatedthe relationshipbetween elevatedcysteine concentrations and cardiovasculardisease (19) (20) (21) (22) (23) (24) (25) (26) . Onlyone study reported on ar ole of hypercysteinemia in venous thrombosis (20) .I nt hat study,hypercysteinemia [OR=2.9 (95%CI 1.1-7.8)]and hyperhomocysteinemia [OR=8.0 (95%CI 3.6-18.0)] were both risk factorsfor venous thrombosis;however,theydid not adjustfor methionine levels.
In conclusion,wefound lowfasting methionine to be arisk factor forrecurrentvenous thrombosis. This risk association was strongerf or methionine than for homocysteine and cysteine. This observation supports the hypothesis that impairedmethylation mayp layar ole in the development of recurrent venous thrombosis in hyperhomocysteinemia.
